Compare Divis Laboratories with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs IPCA LABS - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES IPCA LABS DIVIS LABORATORIES/
IPCA LABS
 
P/E (TTM) x 51.1 27.9 183.3% View Chart
P/BV x 11.8 8.7 135.4% View Chart
Dividend Yield % 0.5 0.1 372.3%  

Financials

 DIVIS LABORATORIES   IPCA LABS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
IPCA LABS
Mar-19
DIVIS LABORATORIES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,6391,042 157.3%   
Low Rs1,115590 189.0%   
Sales per share (Unadj.) Rs186.3298.6 62.4%  
Earnings per share (Unadj.) Rs51.035.0 145.6%  
Cash flow per share (Unadj.) Rs57.349.4 115.9%  
Dividends per share (Unadj.) Rs16.003.00 533.3%  
Dividend yield (eoy) %1.20.4 316.0%  
Book value per share (Unadj.) Rs261.8247.1 105.9%  
Shares outstanding (eoy) m265.47126.35 210.1%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x7.42.7 270.5%   
Avg P/E ratio x27.023.3 115.9%  
P/CF ratio (eoy) x24.016.5 145.6%  
Price / Book Value ratio x5.33.3 159.3%  
Dividend payout %31.48.6 366.3%   
Avg Mkt Cap Rs m365,592103,108 354.6%   
No. of employees `00011.813.4 88.1%   
Total wages/salary Rs m5,4237,874 68.9%   
Avg. sales/employee Rs Th4,175.12,807.0 148.7%   
Avg. wages/employee Rs Th457.7585.8 78.1%   
Avg. net profit/employee Rs Th1,141.8329.0 347.1%   
INCOME DATA
Net Sales Rs m49,46337,732 131.1%  
Other income Rs m1,556577 269.8%   
Total revenues Rs m51,01938,309 133.2%   
Gross profit Rs m18,7186,901 271.3%  
Depreciation Rs m1,6891,824 92.6%   
Interest Rs m35189 18.5%   
Profit before tax Rs m18,5515,465 339.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0231,042 481.9%   
Profit after tax Rs m13,5274,422 305.9%  
Gross profit margin %37.818.3 206.9%  
Effective tax rate %27.119.1 142.0%   
Net profit margin %27.311.7 233.3%  
BALANCE SHEET DATA
Current assets Rs m46,50123,778 195.6%   
Current liabilities Rs m8,46810,975 77.2%   
Net working cap to sales %76.933.9 226.6%  
Current ratio x5.52.2 253.5%  
Inventory Days Days131104 126.1%  
Debtors Days Days8666 130.2%  
Net fixed assets Rs m25,79720,368 126.7%   
Share capital Rs m531253 210.1%   
"Free" reserves Rs m68,96230,971 222.7%   
Net worth Rs m69,49331,224 222.6%   
Long term debt Rs m01,409 0.0%   
Total assets Rs m80,38345,507 176.6%  
Interest coverage x531.030.0 1,772.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 74.2%   
Return on assets %16.910.1 166.5%  
Return on equity %19.514.2 137.4%  
Return on capital %26.717.3 154.4%  
Exports to sales %045.9 0.0%   
Imports to sales %24.616.6 148.4%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs m12,1876,266 194.5%   
Fx inflow Rs m41,23817,308 238.3%   
Fx outflow Rs m12,4056,266 198.0%   
Net fx Rs m28,83311,042 261.1%   
CASH FLOW
From Operations Rs m9,5434,923 193.9%  
From Investments Rs m-6,854-1,563 438.5%  
From Financial Activity Rs m-2,459-1,832 134.2%  
Net Cashflow Rs m2301,528 15.0%  

Share Holding

Indian Promoters % 52.0 45.9 113.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 11.4 103.5%  
FIIs % 19.0 25.3 75.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 17.4 98.9%  
Shareholders   31,796 36,892 86.2%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  ASTRAZENECA PHARMA  BIOCON   

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; Smallcap Stocks Outperform(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended marginally lower.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Oct 22, 2020 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS